S037 The Quality Improvement and Innovation Symposium
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The QI Symposium will feature of panel of QI experts in dermatology from various practice settings (academics, industry, & private practice) who will discuss QI implementation in their careers and provide a framework for incorporating QI into daily practice or future career goals. The symposium will also feature the AAD's Resident Quality Improvement Award and Innovations in Quality Improvement Award Recipients. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Discuss ways in which quality improvement or quality assurance can be integrated into clinical care or research careers across various settings, such as private practice, industry, and academic practice.
Recognize areas of opportunity within their own practice to implement quality improvement methods or models.
SCHEDULE
9:00 PM
Introduction
Martina J Porter, MD, FAAD
9:05 PM
Innovations in QI Awardee: Decreasing After-Hours Charting through Coaching and Workflow Redesign: A Quality Improvement Intervention for Physician Wellbeing
Julianne Anderson Mann, MD, FAAD
9:35 PM
Resident QI award winners (note times are approximate)
Lauren Chen, MD, Charles Dunn, MD, Morgan Nguyen, MD, Kira Rose-Madison Seiger, MD, MBA, Raghav Tripathi, MPH, MD, Zizi Yu, MD
9:35 PM
Vaccines and Dermatology: Expanding the Role of Dermatology Clinics in the Name of Public Health
Charles Dunn, MD
9:45 PM
Individualized Care in Hidradenitis Suppurativa: A Three-Pronged Intervention to Decrease Emergency Department Utilization
Raghav Tripathi, MPH, MD
9:55 PM
Minimizing costs, increasing efficiency, and reducing waste with dermatologic surgery tray optimization: A resident-led quality improvement initiative
Lauren Chen, MD
10:05 PM
Streamlining the Dermatology Prior Authorization Process through Implementation of a Referral-Based Work Queue: Experience from an Urban Safety Net Hospital
Zizi Yu, MD
10:15 PM
Optimizing Cutaneous Oncology Tumor Board
Morgan Nguyen, MD
10:25 PM
Access to Language Concordant Educational Materials for Patients with Preferred Languages Other than English (PLOE) at Medical and Surgical Dermatology Visits
Fiatsogbe Setutsi Dzuali, Kira Rose-Madison Seiger, MD, MBA
11:00 PM
Dermatology Careers in QI Panel Discussion
Martina J Porter, MD, FAAD, Betty Ann Hinderks Davis, MD, FAAD, Rita Khodosh, MD, PhD, FAAD, Justin Ko, MD, MBA, FAAD
SPEAKERS
Lauren Chen, MD
Betty Ann Hinderks Davis, MD, FAAD
Charles Dunn, MD
Fiatsogbe Setutsi Dzuali
Rita Khodosh, MD, PhD, FAAD
Justin Ko, MD, MBA, FAAD
Julianne Anderson Mann, MD, FAAD
Morgan Nguyen, MD
Martina J Porter, MD, FAAD
Kira Rose-Madison Seiger, MD, MBA
Raghav Tripathi, MPH, MD
Zizi Yu, MD
SPEAKER DISCLOSURES
Lauren Chen, MD
No financial relationships exist with ineligible companies.
Betty Ann Hinderks Davis, MD, FAAD
Castle Biosciences, Inc – Investigator(Fees);
Charles Dunn, MD
No financial relationships exist with ineligible companies.
Fiatsogbe Setutsi Dzuali
No financial relationships exist with ineligible companies.
Rita Khodosh, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Justin Ko, MD, MBA, FAAD
Eli Lilly and Company – Consultant(Fees); Enspectra Health – Consultant(Fees), Consultant(Stock Options); Google Research – Investigator(Grants/Research Funding); Hims – Consultant(Fees); Pfizer Inc. – Consultant(Fees); Skin Analytics – Advisory Board(Stock Options), Consultant(Fees);
Julianne Anderson Mann, MD, FAAD
No financial relationships exist with ineligible companies.
Morgan Nguyen, MD
No financial relationships exist with ineligible companies.
Martina J Porter, MD, FAAD
AbbVie – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Alumis – Consultant(Fees); AnaptysBio – Investigator(Grants/Research Funding); Bayer – Investigator(Grants/Research Funding); Beth Israel Deaconess Medical Center – Other(Patent royalties or other compensation for Intellectual Property Rights); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(No Compensation Received); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Consultant(Fees); Mirador – Investigator(Grants/Research Funding); Moonlake – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); National Psoriasis Foundation – Speaker(Honoraria); Novartis – Consultant(Fees), Investigator(Grants/Research Funding); Oasis Pharmaceuticals – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Prometheus Laboratories, Inc. – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Trifecta Clinical – Consultant(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Zura Bio – Consultant (1099 relationship)(Fees);
Kira Rose-Madison Seiger, MD, MBA
No financial relationships exist with ineligible companies.
Raghav Tripathi, MPH, MD
No financial relationships exist with ineligible companies.
Zizi Yu, MD
No financial relationships exist with ineligible companies.